港股詳情

本頁面由Tiger Fintech (Singapore) Pte. Ltd.提供服務

高瓴概念

473.358

+1.9750.42%

漲家數：30

跌家數：18

平家數：7

市盈率：- -

高：480.368

開：471.419

低：469.310

收：471.383

資料載入中...

信達生物(01801.HK)第一季總收入逾24億人民幣保持40%以上增長

阿斯达克财经

南京華脈科技股份有限公司中標中國鐵塔河南省分公司4.9GHz頻段POI產品研發服務項目

活力集團重新遞交上市申請書：創始人投資過美團，去年賣出1.3億張票

红星资本局

21Shares 已向美 SEC 提交 SUI ETF 的 S-1 註冊表

21Shares 已向美 SEC 提交 SUI ETF 的 S-1 註冊表

翰森製藥：B7-H4靶向抗體-藥物偶聯物HS-20089獲國藥監局納入突破性治療藥物

翰森製藥(03692)：B7-H4靶向抗體-藥物偶聯物HS-20089獲國藥監局納入突破性治療藥物

信達生物(01801)第一季度總產品收入超24億元，同比保持40%以上的強勁增長

海南自貿港“零關税”進口藥品、醫療器械政策享惠貨值突破6000萬元

中国经济网

海南自貿港“零關税”進口藥品、醫療器械政策享惠貨值突破6000萬元

彭博社：橋水基金前量化分析師Varun Kao加入Bitwise

彭博社：橋水基金前量化分析師Varun Kao加入Bitwise

中國信達資產管理股份有限公司啓動2025年IT運維外包服務招標

中國鐵塔股份有限公司四川省分公司輸氣管線監控服務項目啓動招標

朱海馬擬任生命保險資產董事長，壽險帥位空缺下或有接任可能

平安資管總經理辭任！

百濟神州參投，可編程 mRNA實現 IL-12瘤內定向激活，開啓“mRNA 2.0”

保利物業：料核心經營穩中有進持續重視股東回報

榮昌生物：收入快速增長泰它西普GMG數據超預期

泰格醫藥回購股份方案實施期限屆滿

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1583/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1583","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1583\",,,,,undefined,":{"symbol":"BK1583","market":"HK","secType":"PLATE","nameCN":"高瓴概念","latestPrice":473.35806,"timestamp":1746000495834,"preClose":471.3829,"halted":0,"volume":449463537,"delay":0,"changeRate":0.00419,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未開盤","change":1.975159,"latestTime":"04-30 16:00:00","open":471.41876,"high":480.36774,"low":469.31015,"amount":12553014206,"amplitude":0.023458,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1746149400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1745976600000,1745985600000],[1745989200000,1746000000000]],"pbRate":2.238051,"peRate":21.705564,"turnoverRate":0.003086,"increases":30,"decrements":22,"flats":2,"marketCap":2669831540224,"floatMarketCap":2093905376768},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1583\",,,,,undefined,":{"symbol":"BK1583","high":480.36774,"amplitude":0.023458,"preClose":471.3829,"low":469.31015,"pbRate":"2.238051","latestPrice":473.35806,"volume":449463537,"delay":0,"open":471.41876,"prevYearClose":446.93042,"prevWeekClose":466.075,"prevMonthClose":473.358,"prevQuarterClose":505.776,"fiveDayClose":474.384,"twentyDayClose":512.397,"sixtyDayClose":448.401,"secType":"PLATE","market":"HK","turnoverRate":0.003086,"peRate":21.705564,"marketCap":2669831540224,"floatMarketCap":2093905376768,"timestamp":1746000495834,"nameCN":"高瓴概念"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1583\",,,,undefined,":{"bkCode":"BK1583","up":30,"down":18,"flat":7},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1583\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2532009148","title":"信達生物(01801.HK)第一季總收入逾24億人民幣  保持40%以上增長","url":"https://stock-news.laohu8.com/highlight/detail?id=2532009148","media":"阿斯达克财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532009148?lang=zh_tw&edition=fundamental","pubTime":"2025-05-01 22:46","pubTimestamp":1746110760,"startTime":"0","endTime":"0","summary":"信达生物(01801.HK) 公布，今年第一季度，共取得总产品收入超过24亿人民币，按年保持40%以上增长。季内，成功上市四款新药，包括肿瘤领域的达伯乐、奥壹新、捷帕力及综合产品线领域的信必敏。至今，公司已取得15款产品获批上市，3个品种在中国国家药品监督管理局审评中，4个新药分子进入3期或关键性临床研究，另外约15个新药品种已进入临床研究。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2025-04-30 16:25。)AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20220906114108815_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20220906114108815_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1437359/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1589","LU2488822045.USD","BK1583","LU1969619763.USD","BK1161","01801","LU2328871848.SGD"],"gpt_icon":0},{"id":"2532072585","title":"南京華脈科技股份有限公司中標中國鐵塔河南省分公司4.9GHz頻段POI產品研發服務項目","url":"https://stock-news.laohu8.com/highlight/detail?id=2532072585","media":"iDoNews","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532072585?lang=zh_tw&edition=fundamental","pubTime":"2025-05-01 20:36","pubTimestamp":1746102962,"startTime":"0","endTime":"0","summary":"天眼查App显示，2025年04月30日，中国铁塔股份有限公司河南省分公司公布了2025年支持4.9GHz频段的POI产品研发服务采购项目（第二次）的中选结果。该项目已完成中选候选人公示且无异议，最终确定南京华脉科技股份有限公司为中选人。中选报价为综合折扣系数94%。公示期自2025年04月30日至2025年05月06日，共计7天。此次公告发布媒介包括中国招标投标公共服务平台、中国铁塔在线商务平台和中国铁塔电子采购平台。采购人地址位于河南省自贸试验区郑州片区（郑东）祥盛街8号附1号1号楼13层。免责声明：本文内容由开放的智能模型自动生成，仅供参考。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050120374494e9eecd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050120374494e9eecd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02943","BK1506","BK1529","IE00BG0RBZ43.SGD","BK1521","BK1181","LU0823413587.USD","BK1190","IE00BHRH8C09.USD","LU0823413660.USD","BK1589","603042","IE00BHRH8D16.HKD","BK1133","BK1583","00788"],"gpt_icon":0},{"id":"2532007901","title":"活力集團重新遞交上市申請書：創始人投資過美團，去年賣出1.3億張票","url":"https://stock-news.laohu8.com/highlight/detail?id=2532007901","media":"红星资本局","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532007901?lang=zh_tw&edition=fundamental","pubTime":"2025-05-01 19:48","pubTimestamp":1746100080,"startTime":"0","endTime":"0","summary":"4月30日，活力集团控股有限公司向港交所重新递交了上市申请书，联席保荐人为招商证券国际、民银资本。另外，红星资本局注意到，活力集团的联合创始人曾投资过美团，而王兴的名字也出现在活力集团的股东名单中，但不确定此王兴是否为美团的创始人王兴。以2024年为例，活力集团售出3390万张机票，售出9450万张火车票。目前，王兴持有活力集团约886.21万股股票，持股比例约为2.28%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250501200558a6d000c7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250501200558a6d000c7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0164872284.USD","LU1770036033.HKD","LU0196878994.USD","LU0228659784.USD","LU2097828631.EUR","LU0084288322.USD","LU0594300419.USD","LU1831875114.USD","LU0214875030.USD","LU0315178854.USD","BK1583","BK1615","LU0828237940.HKD","LU1770034418.SGD","LU0449515922.USD","LU0865486749.SGD","LU0049853897.USD","HMTD.SI","IE00BF5LJ272.USD","LU1152091754.HKD","LU0326950275.SGD","LU1224709979.USD","LU0823039010.USD","LU0348825331.USD","LU0823040885.USD","LU1226287529.USD","LU1481107354.HKD","LU0708995583.HKD","LU0165289439.USD","LU0052750758.USD","LU0348788117.USD","LU1102505762.USD","BK1575","LU0502904849.HKD","LU0650527681.SGD","LU0417516902.SGD","LU1282648689.USD","LU0287142896.SGD","83690","LU0054450605.USD","LU0918141887.USD","LU0589944569.HKD","LU0173614495.USD","LU0359201885.HKD","LU1008478684.HKD","03690","LU0164880469.USD","SG9999014674.SGD","LU0327786744.USD","LU2242644610.SGD"],"gpt_icon":1},{"id":"2532133073","title":"21Shares 已向美 SEC 提交 SUI ETF 的 S-1 註冊表","url":"https://stock-news.laohu8.com/highlight/detail?id=2532133073","media":"BitPush","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532133073?lang=zh_tw&edition=fundamental","pubTime":"2025-05-01 19:06","pubTimestamp":1746097565,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bitpush.news//articles/7425711","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"bit_push_live","symbols":["BK4228","BK1258","BK1542","BK1229","BK4550","FDN","BK4588","SEC.AU","BK1583","BK4215","SUI","BK4585","09983"],"gpt_icon":0},{"id":"2532732200","title":"21Shares 已向美 SEC 提交 SUI ETF 的 S-1 註冊表","url":"https://stock-news.laohu8.com/highlight/detail?id=2532732200","media":"foresightnews","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532732200?lang=zh_tw&edition=fundamental","pubTime":"2025-05-01 18:58","pubTimestamp":1746097080,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://foresightnews.pro/foresightnews/news/detail/71854","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"foresightnews_live","symbols":["IE00B19Z3B42.SGD","LU1983260115.SGD","SG9999014914.USD","LU1316542783.SGD","BK4550","SG9999014906.USD","LU1064131342.USD","09983","LU2087625088.SGD","BK4230","LU0642271901.SGD","LU1988902786.USD","LU2360107325.USD","BK1583","BK4503","BK4228","LU1861214812.USD","LU0353189680.USD","SGXZ31699556.SGD","IE00B7SZLL34.SGD","BK4551","LU0127658192.USD","GB00BDT5M118.USD","UBER","IE00BZ199S13.USD","SG9999015945.SGD","BK4536","LU0006306889.USD","SEC.AU","BK1258","LU0082616367.USD","LU1861219969.SGD","LU0106261372.USD","SUI","SG9999015978.USD","IE0002270589.USD","LU0353189763.USD","BK1229","BK4505","LU0719512351.SGD","BK1542","SG9999018857.SGD","BK4588","SG9999015952.SGD","BK4022","SG9999014898.SGD","SG9999017495.SGD","LU1814569148.SGD","FDN","SG9999018865.SGD"],"gpt_icon":0},{"id":"2532797078","title":"翰森製藥：B7-H4靶向抗體-藥物偶聯物HS-20089獲國藥監局納入突破性治療藥物","url":"https://stock-news.laohu8.com/highlight/detail?id=2532797078","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532797078?lang=zh_tw&edition=fundamental","pubTime":"2025-05-01 18:57","pubTimestamp":1746097020,"startTime":"0","endTime":"0","summary":"翰森制药发布公告，于2025年5月1日，集团自研B7-H4靶向抗体-...翰森制药发布公告，于2025年5月1日，集团自研B7-H4靶向抗体-药物偶联物注射用HS-20089获中国国家药品监督管理局批准纳入突破性治疗药物，拟定适应症为用于铂耐药复发上皮性巢癌、输管癌或原发性腹膜癌患者。据悉，HS-20089是一种B7-H4靶向ADC，其有效载荷为拓扑异构酶抑制剂，正于中国开展用于治疗巢癌以及其他妇科肿瘤的多项临床研究，其中最高研究阶段为临床III期。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250501185942a46ed24e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250501185942a46ed24e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1583","BK1589","03692"],"gpt_icon":0},{"id":"2532200170","title":"翰森製藥(03692)：B7-H4靶向抗體-藥物偶聯物HS-20089獲國藥監局納入突破性治療藥物","url":"https://stock-news.laohu8.com/highlight/detail?id=2532200170","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532200170?lang=zh_tw&edition=fundamental","pubTime":"2025-05-01 18:49","pubTimestamp":1746096552,"startTime":"0","endTime":"0","summary":"智通财经APP讯，翰森制药 发布公告，于2025年5月1日，集团自研B7-H4靶向抗体-药物偶联物注射用HS-20089获中国国家药品监督管理局批准纳入突破性治疗药物，拟定适应症为用于铂耐药复发上皮性卵巢癌、输卵管癌或原发性腹膜癌患者。据悉，HS-20089是一种B7-H4靶向ADC，其有效载荷为拓扑异构酶抑制剂，正于中国开展用于治疗卵巢癌以及其他妇科肿瘤的多项临床研究，其中最高研究阶段为临床III期。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1288808.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"翰森制药(03692)：B7-H4靶向抗体-药物偶联物HS-20089获国药监局纳入突破性治疗药物","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1583","03692","BK1589"],"gpt_icon":0},{"id":"2532022948","title":"信達生物(01801)第一季度總產品收入超24億元，同比保持40%以上的強勁增長","url":"https://stock-news.laohu8.com/highlight/detail?id=2532022948","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532022948?lang=zh_tw&edition=fundamental","pubTime":"2025-05-01 18:05","pubTimestamp":1746093913,"startTime":"0","endTime":"0","summary":"智通财经APP讯，信达生物 发布公告，于2025年第一季度，公司共取得总产品收入超人民币24亿元，同比保持40%以上的强劲增长。其中：1)公司在肿瘤治疗领域已树立领导品牌，达伯舒 等主要产品保持快速的增长态势，新产品收入贡献加速提升;及2)综合产品线潜力逐渐释放，信必乐 新进入国家医保目录生效，信必敏 成功获批上市用于治疗甲状腺眼病，为增长贡献新驱动力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1288803.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01801","LU1969619763.USD","BK1589","LU2328871848.SGD","BK1161","BK1583","LU2488822045.USD"],"gpt_icon":0},{"id":"2532293220","title":"海南自貿港“零關税”進口藥品、醫療器械政策享惠貨值突破6000萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2532293220","media":"中国经济网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532293220?lang=zh_tw&edition=fundamental","pubTime":"2025-05-01 15:55","pubTimestamp":1746086100,"startTime":"0","endTime":"0","summary":"转自：新华社　　记者5月1日从海口海关获悉，海南自由贸易港“零关税”进口药品、医疗器械政策自2024年12月25日在博鳌乐城国际医疗旅游先行区落地实施以来，已有10家医院通过政策享惠主体审核。海口海关共监管“零关税”进口药品、医疗器械申报总货值6023.9万元人民币，减免税款818.7万元人民币。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2025-05-01/doc-ineuzzea0802285.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-05-01/doc-ineuzzea0802285.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09997","09996","BK1100","BK1222","BK1574","BK1583","159883"],"gpt_icon":0},{"id":"2532258500","title":"海南自貿港“零關税”進口藥品、醫療器械政策享惠貨值突破6000萬元","url":"https://stock-news.laohu8.com/highlight/detail?id=2532258500","media":"美港电讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532258500?lang=zh_tw&edition=fundamental","pubTime":"2025-05-01 15:51","pubTimestamp":1746085913,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.ushknews.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_meigang","symbols":["BK1222","159891","BK1574","BK1100","BK1583","09997","09996","159883"],"gpt_icon":0},{"id":"2532023106","title":"彭博社：橋水基金前量化分析師Varun Kao加入Bitwise","url":"https://stock-news.laohu8.com/highlight/detail?id=2532023106","media":"金色财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532023106?lang=zh_tw&edition=fundamental","pubTime":"2025-05-01 15:40","pubTimestamp":1746085241,"startTime":"0","endTime":"0","summary":null,"market":null,"thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.bloomberg.com/news/articles/2025-04-30/bridgewater-quant-analyst-among-crypto-asset-manager-bitwise-s-new-hires","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinse_live","symbols":["09983","BK1258","BK4135","BK1229","BK4585","BK1542","LU1699723380.USD","BK4559","LU0648001328.SGD","BK4588","BK","LU0980610538.SGD","LU0477156953.USD","LU1571399168.USD","BK1583","LU1201861249.SGD","LU0130102774.USD","LU0130517989.USD"],"gpt_icon":0},{"id":"2532253260","title":"彭博社：橋水基金前量化分析師Varun Kao加入Bitwise","url":"https://stock-news.laohu8.com/highlight/detail?id=2532253260","media":"Blockbeats","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532253260?lang=zh_tw&edition=fundamental","pubTime":"2025-05-01 15:38","pubTimestamp":1746085080,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.theblockbeats.info//flash/292039","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"theblockbeats_zh_live","symbols":["LU1699723380.USD","LU0477156953.USD","BK4559","BK1258","BK1542","BK1229","LU0130517989.USD","LU0648001328.SGD","LU0130102774.USD","BK4588","BK4135","LU1571399168.USD","BK1583","LU1201861249.SGD","BK","LU0980610538.SGD","BK4585","09983"],"gpt_icon":0},{"id":"2532366040","title":"中國信達資產管理股份有限公司啓動2025年IT運維外包服務招標","url":"https://stock-news.laohu8.com/highlight/detail?id=2532366040","media":"iDoNews","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532366040?lang=zh_tw&edition=fundamental","pubTime":"2025-05-01 14:39","pubTimestamp":1746081542,"startTime":"0","endTime":"0","summary":"天眼查App显示，2025年4月30日，中国信达资产管理股份有限公司在北京市发布了2025年总部IT运维外包服务采购项目的招标公告。该项目旨在通过公开招标选择一家合格的供应商，提供为期3年的IT运维外包服务。具体服务内容包括解决总部机房、桌面、会议系统和资源维护方面的运维需求，并计划采购17名IT运维外包人员的技术服务。服务期限为2025年10月1日至2028年9月30日，合同一年一签，可续签不超过2次。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050114392894e9b88c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050114392894e9b88c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09983","BK1156","BK1229","BK1583","01359","BK1542","BK1258"],"gpt_icon":0},{"id":"2532040526","title":"中國鐵塔股份有限公司四川省分公司輸氣管線監控服務項目啓動招標","url":"https://stock-news.laohu8.com/highlight/detail?id=2532040526","media":"iDoNews","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532040526?lang=zh_tw&edition=fundamental","pubTime":"2025-05-01 14:30","pubTimestamp":1746081002,"startTime":"0","endTime":"0","summary":"天眼查App显示，2025年4月30日，中国铁塔股份有限公司四川省分公司发布了一项关于宜宾市分公司2025年输气管线阶段点位监控服务的采购项目招标公告。该项目计划采购输气管线阶段点位监控服务，预估不含税总金额为90.8万元人民币，适用增值税税率为6%，含税总金额为96.248万元人民币。供应商需在2025年5月1日至2025年5月7日期间通过中国铁塔电子采购平台获取比选文件，每套售价300元人民币。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050114310094e9b756&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025050114310094e9b756&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["00788","IE00BHRH8D16.HKD","IE00BHRH8C09.USD","BK1589","BK1181","LU0823413587.USD","BK1521","IE00BG0RBZ43.SGD","BK1583","BK1506","BK1133","02943","LU0823413660.USD","BK1529","BK1190"],"gpt_icon":0},{"id":"2532044932","title":"朱海馬擬任生命保險資產董事長，壽險帥位空缺下或有接任可能","url":"https://stock-news.laohu8.com/highlight/detail?id=2532044932","media":"机构之家","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532044932?lang=zh_tw&edition=fundamental","pubTime":"2025-05-01 13:13","pubTimestamp":1746076380,"startTime":"0","endTime":"0","summary":"机构之家关注到，4月29日，生命保险资产管理有限公司（以下简称“生命保险资产“）发布两项投资管理能力风险责任人信息披露公告，显示朱海马已任公司衍生品运用(股指期货)管理能力、股票投资管理能力风险责任人，其职务也已明确为公司拟任董事长。来源：公司公告朱海马为集团悍将，寿险帅位空缺下或有接任可能履历显示，朱海马的富德生涯起于寿险领域。2014年主政富德富德生命人寿海南分公司时，正值保险业“资产驱动负债","market":"hk","thumbnail":"http://imgcloud.jrjimg.cn/2025/05/weixin/one_20250501131320104.png","type":0,"news_type":0,"thumbnails":["http://imgcloud.jrjimg.cn/2025/05/weixin/one_20250501131320104.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://insurance.jrj.com.cn/2025/05/01131350073646.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1542","BK1583","09983","BK1258","BK1229"],"gpt_icon":0},{"id":"2532015160","title":"平安資管 總經理辭任！","url":"https://stock-news.laohu8.com/highlight/detail?id=2532015160","media":"券商中国","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532015160?lang=zh_tw&edition=fundamental","pubTime":"2025-05-01 07:27","pubTimestamp":1746055658,"startTime":"0","endTime":"0","summary":"4月30日，平安资产管理有限责任公司（下称“平安资管”）发布公告称，经公司4月24日第七届董事会第十五次会议审议通过，总经理罗水权因工作调整不再担任公司总经理职务。为保证公司持续有效经营，董事会指定董事长黄勇兼任总经理临时负责人，代行总经理职权。平安资管表示，此次人事变动不会对公司正常经营产生影响，目前公司治理架构稳定，人才梯队完备，各项工作有序开展。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202505013394962161.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1542","BK1583","09983","BK1258","BK1229"],"gpt_icon":0},{"id":"2532101739","title":"百濟神州參投，可編程 mRNA實現 IL-12瘤內定向激活，開啓“mRNA 2.0”","url":"https://stock-news.laohu8.com/highlight/detail?id=2532101739","media":"动脉网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532101739?lang=zh_tw&edition=fundamental","pubTime":"2025-05-01 07:21","pubTimestamp":1746055260,"startTime":"0","endTime":"0","summary":"Strand Therapeutics展示了一种可编程mRNA疗法STX-003，能精准调控IL-12在肿瘤组织的表达，提高耐受性并维持抗肿瘤疗效，其核心优势在于自复制mRNA与遗传电路的结合，为肿瘤治疗提供创新策略。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250501094317974c26cc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250501094317974c26cc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1500","LU1969619763.USD","BK1588","688235","06160","LU0588546209.SGD","BK1161","LU0307460666.USD","BK1583","ONC","LU2328871848.SGD"],"gpt_icon":0},{"id":"2532496025","title":"保利物業：料核心經營穩中有進 持續重視股東回報","url":"https://stock-news.laohu8.com/highlight/detail?id=2532496025","media":"中金公司","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532496025?lang=zh_tw&edition=fundamental","pubTime":"2025-05-01 00:00","pubTimestamp":1746028800,"startTime":"0","endTime":"0","summary":"公司近况保利物业近期参加了我们为其组织的反向路演活动，并与投资人交流公司经营近况。评论料竞标外拓稳中有进推动基础板块健康增长。经营性现金流有一定支撑，管理层重视股东回报。2024 年，公司经营性现金流净额23.0 亿元，对归母净利润的覆盖倍数为1.6 倍；我们认为考虑到公司在前端项目获取层面加强对项目回款的评估，以及对物业费收缴、预缴层面的重视程度，预计2025 年经营性现金流仍有一定支撑。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250501160208a6cfcef6&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250501160208a6cfcef6&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06049","BK1229","LU0348767384.USD","BK1258","LU0348766576.USD","BK1583","BK1589","BK1542","LU0082770016.USD"],"gpt_icon":0},{"id":"2532107630","title":"榮昌生物：收入快速增長 泰它西普GMG數據超預期","url":"https://stock-news.laohu8.com/highlight/detail?id=2532107630","media":"中金公司","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2532107630?lang=zh_tw&edition=fundamental","pubTime":"2025-05-01 00:00","pubTimestamp":1746028800,"startTime":"0","endTime":"0","summary":"1Q25 公司收入同比增长59.17%，我们估计泰它西普和维迪西妥单抗销量均有较好增长。泰它西普治疗全身型重症肌无力III 期临床试验数据优异。由于泰它西普gMG 数据超我们预期，有望打开该适应症的全球市场空间，基于DCF 模型，我们维持公司跑赢行业评级，上调目标价40.6%至45 港币，较当前股价有21.8%的上行空间。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250501101259a46e6e0b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250501101259a46e6e0b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU1969619763.USD","BK1161","LU2328871848.SGD","BK1583","BK1574","09995"],"gpt_icon":0},{"id":"2531052981","title":"泰格醫藥回購股份方案實施期限屆滿","url":"https://stock-news.laohu8.com/highlight/detail?id=2531052981","media":"DoNews","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2531052981?lang=zh_tw&edition=fundamental","pubTime":"2025-04-30 23:16","pubTimestamp":1746026161,"startTime":"0","endTime":"0","summary":"4月30日，泰格医药发布公告称，公司回购股份方案实施期限已届满。截至当日，通过集中竞价交易方式累计回购9,806,300股，占总股本1.1337%。此举旨在优化资本结构并维护股东利益。免责声明：本文内容由开放的智能模型自动生成，仅供参考。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025043023242594e91e60&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025043023242594e91e60&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1576","BK1141","BK1583","03347"],"gpt_icon":0}],"pageSize":20,"totalPage":43,"pageCount":1,"totalSize":860,"code":"91000000","status":"200"}]}}